Azenta, Inc. (AZTA)
| Market Cap | 1.12B |
| Revenue (ttm) | 595.03M |
| Net Income (ttm) | -60.20M |
| Shares Out | 46.06M |
| EPS (ttm) | -1.31 |
| PE Ratio | n/a |
| Forward PE | 25.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 847,767 |
| Open | 24.87 |
| Previous Close | 25.15 |
| Day's Range | 23.71 - 25.23 |
| 52-Week Range | 19.87 - 41.73 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 40.60 (+67.49%) |
| Earnings Date | May 5, 2026 |
About AZTA
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sampl... [Read more]
Financial Performance
In fiscal year 2025, Azenta's revenue was $593.82 million, an increase of 3.55% compared to the previous year's $573.45 million. Losses were -$55.76 million, -66.18% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AZTA stock is "Strong Buy." The 12-month stock price target is $40.6, which is an increase of 67.49% from the latest price.
News
Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026.
Azenta Transcript: M&A announcement
The acquisition expands European presence, leverages automation synergies, and positions for scalable growth in life sciences. Minimal CapEx is required, with commercial investments driving future revenue and margin expansion. 2026 will be dilutive, but accretive from 2027.
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquire...
Azenta Transcript: 47th Annual Raymond James Institutional Investor Conference
The company is executing a turnaround with a focus on operational excellence, margin expansion, and commercial effectiveness. Key initiatives include decentralization, sales force transformation, and ABS-driven process improvements, with strong free cash flow and EBITDA growth targeted over the next three years.
Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference
BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on...
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduc...
Azenta Earnings Call Transcript: Q1 2026
Q1 revenue was $149M, up 1% reported but down 1% organically, with margin pressures from quality issues and regional mix. FY2026 guidance for 3%-5% organic growth and 300 bps EBITDA margin expansion reaffirmed, with acceleration expected in the second half as investments and market conditions improve.
Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025
BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025.
Azenta Transcript: AGM 2026
A transformative year featured strong cash reserves, margin expansion, and a $250M share repurchase. Four shareholder proposals, including board elections and an equity plan amendment, were all approved. Strategic plans include divesting B Medical by March 2026.
Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast
BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before t...
Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S.À R.L.
BURLINGTON, Mass. , Dec. 29, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical...
Azenta Transcript: Investor Day 2025
A decentralized structure and operational excellence are driving growth, with biorepositories and gene synthesis regionalization as key initiatives. Financial targets include doubling EBITDA and reaching $700M-$750M revenue by 2028, supported by disciplined capital allocation and a robust M&A pipeline.
Azenta Authorizes $250 Million Share Repurchase Program
BURLINGTON, Mass. , Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase...
Azenta Earnings Call Transcript: Q4 2025
Fiscal 2025 saw 3% core growth and 310 bps margin expansion, with strong cash flow and a robust balance sheet. Guidance for 2026 targets 3%-5% organic growth, 300 bps EBITDA margin expansion, and improved free cash flow, despite macro headwinds and a slow Q1 start.
Azenta Reports Fourth Quarter and Full Year Fiscal 2025 Results, Ended September 30, 2025
Q4'25 reported revenue growth of 6% year over year and 4% on an organic basis FY'25 reported revenue growth of 4% and 3% on an organic basis FY'25 Adjusted EBITDA margin expansion of 310 basis points ...
Azenta Announces Fiscal 2025 Fourth Quarter and Full Year Conference Call and Webcast
BURLINGTON, Mass. , Nov. 12, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2025 earnings which ended on September 30, 2025, on Friday, November 21,...
Azenta Life Sciences Partners with PRECEDE Foundation to Advance Early Detection of Pancreatic Cancer
BURLINGTON, Mass. , Nov. 4, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-institutional collaborative fo...
Azenta to Host Investor Day at its Biorepository Facility in Indianapolis, Indiana
BURLINGTON, Mass. , Oct. 15, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it will host an Investor Day on Wednesday, December 10, 2025, at the Company's biorepository facility...
Azenta Earnings Call Transcript: Q3 2025
Q3 2025 revenue was flat year-over-year at $144 million, with adjusted EBITDA margin expanding 260 basis points to 12.3%. Guidance for 3%-5% organic revenue growth and 300 basis points of margin expansion was reaffirmed, supported by strong NGS and Sample Storage performance and robust cash reserves.
Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance
BURLINGTON, Mass. , Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025.
Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology
BURLINGTON, Mass. , July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, ...
Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care
Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated geno...
Azenta to Participate in 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass. , July 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conf...
Azenta Announces Fiscal 2025 Third Quarter Earnings Conference Call and Webcast
BURLINGTON, Mass. , July 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the marke...
Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass.